MC3R Genotype

If you went through puberty noticeably later than your peers, ended up shorter than your family pattern would predict, or have struggled with weight since childhood, part of that experience may be written into a single gene. MC3R (melanocortin-3 receptor) is one of the brain's signaling components for energy balance and pubertal timing, and your inherited version of it may shape how you store fat, how hungry you feel, and when puberty arrived.

This test reads the specific letters of your MC3R gene. It will not change over your lifetime, and one result is enough to inform decades of decisions about weight, metabolism, growth, and family planning.

What MC3R Actually Does

MC3R is a receptor (a docking station on the surface of cells that receives chemical signals) that sits mostly in the hypothalamus, the part of your brain that controls hunger and energy use. It is also found in the pancreas, liver, fat tissue, and certain immune cells. Animal research suggests it helps regulate how much of the calories you eat get burned versus stored as fat, though the human evidence for this specific mechanism is less definitive.

Different versions of the MC3R gene change how well this receptor responds to incoming signals. Some common changes nudge the system slightly. Rare changes can knock down receptor function more dramatically. Both kinds may matter for your weight, your insulin, and the pace at which you grew up.

Growth, Puberty, and Height

The most consistent role of MC3R across recent human research is in growth and pubertal timing. Rare loss-of-function MC3R variants were overrepresented in adolescents with constitutional delay of growth and puberty (the medical term for going through puberty noticeably later than peers without a clear cause), with an odds ratio of 4.17 compared with controls. Researchers noted that these variants are not a common cause of this phenotype but are meaningfully enriched. In a separate cohort of people with obesity, MC3R loss-of-function variants were also linked to shorter adult height and later puberty.

A 2025 cross-species study of roughly 300,000 individuals concluded that MC3R's role in pubertal development is more consistent than its role in energy balance. If your puberty arrived late and your adult height ended up shorter than your family pattern would predict, an inherited MC3R variant is one biological explanation worth knowing about.

Obesity and Body Fat: A More Uncertain Picture

For years, MC3R was studied primarily as an obesity gene. The picture has become more nuanced. A 2019 systematic review and meta-analysis of six studies (about 2,969 obese and 2,572 normal-weight individuals) reported an odds ratio of 3.07 (95% CI, 1.48 to 7.00) for obesity in carriers of rare loss-of-function variants. The wide confidence interval reflects substantial uncertainty, and the pooled sample was relatively small.

A much larger 2025 cross-species study of about 300,000 individuals identified nine people homozygous for functionally null MC3R variants and found that complete loss of MC3R does not result in a penetrant human obesity syndrome. Case-control studies have also failed to consistently show enrichment of the common Thr6Lys and Val81Ile variants in obese populations, and their effect may only emerge once obesity is already present.

That said, two common changes, Thr6Lys and Val81Ile, may matter when inherited together. In one study, children who carried both changes on both copies of the gene were heavier and had higher leptin (a hormone that signals fullness), higher insulin, and more insulin resistance than children without them. In an Asian cohort, each additional minor allele copy was linked to roughly 1.48 times the odds of overweight and 1.58 times the odds of obesity.

In one pediatric study, children carrying more of these minor versions ate more calories but did not burn fewer. In adult studies, a 10-week low-calorie diet trial in obese Europeans found no clear effect of MC3R variants on how much weight people lost.

Insulin, Fat Burning, and Type 2 Diabetes

MC3R variants may change how your body chooses between burning fat and burning sugar. In offspring of people with type 2 diabetes, carriers of the Lys6 and Ile81 versions burned less fat, burned more glucose, and had higher early insulin responses than non-carriers. That pattern, more sugar-burning and a stronger insulin push, is the kind of metabolic setup associated with weight gain and insulin resistance over time.

Specific MC3R variants (including rs3746619 and rs3827103) have been linked to type 2 diabetes risk in some family studies, and rs3746619 has been associated with higher HbA1c (a three-month average of blood sugar). The evidence is mixed: studies in French Caucasians and in a Maori kindred did not find an association between MC3R coding variants and diabetes. Overall the link is suggestive rather than definitive.

Tuberculosis Susceptibility

One MC3R promoter variant, rs6127698, has been linked to tuberculosis risk in some populations. In a southern Chinese Han cohort, the G allele was linked to higher risk of multifocal tuberculosis (a form of TB that affects multiple sites in the body), and the same variant was tied to TB susceptibility in a South African cohort. The Chinese study reported higher MC3R protein expression in patients.

The picture is not clean. A separate functional study found that rs6127698 did not influence MC3R protein expression in a laboratory assay, suggesting it may be a marker linked to a nearby causal variant rather than the cause itself. An Iranian study reported the opposite risk allele (T, not G) for pulmonary TB. This is a niche finding with conflicting results, but worth knowing about if you have a family history of severe or recurrent TB.

Why Common Lab Panels Miss This

Standard metabolic and lipid testing tells you what your body is doing right now. They do not tell you whether an inherited variant may be shaping your growth trajectory, the timing of puberty, or how your body partitions fat. Two people with identical fasting glucose, HbA1c, and lipid panels can have different underlying genetic backgrounds. The MC3R result can help explain patterns that standard labs cannot, such as late puberty and shorter adult height clustered with childhood-onset weight gain.

One Test, Lifetime Result

Your MC3R genotype is the same the day you are born as the day you die. There is no trend to track and no need to retest unless you want to confirm a result with a different method (for example, Sanger sequencing after a chip-based call). The value comes from acting on the result over years.

What does need tracking, especially if you carry a rare loss-of-function variant, is the downstream phenotype. There are no professional society guidelines that recommend a specific monitoring protocol for MC3R carriers, so any plan is based on clinical judgment rather than guideline. A reasonable starting point with your physician includes weight trajectory, body fat percentage, fasting insulin, HbA1c, lipids, and leptin, with a metabolic baseline now and at least annual follow-up after that.

What to Do If You Carry a Risk Variant

A high-risk MC3R result is not a diagnosis, and MC3R genotyping is not currently a standard-of-care test. It is a signal that the surrounding metabolic picture deserves a closer look. Reasonable next steps to discuss with your clinician include the following:

• Broader metabolic workup: consider fasting insulin, HbA1c, a full lipid panel including ApoB (apolipoprotein B, a count of fat-carrying particles linked to heart disease), leptin, and liver enzymes to map how the variant is showing up in your physiology now. This panel is reasonable clinical practice but is not specifically guideline-based for MC3R carriers.
• Earlier and tighter weight monitoring: because MC3R variants may influence energy intake and fat partitioning, expect weight regulation to be a multi-year project rather than a fix.
• Family conversations: biological children, siblings, and parents each have meaningful odds of carrying the same variant, especially if childhood obesity, late puberty, or short stature runs in the family.
• Specialist input for rare variants: if a loss-of-function variant is identified, an endocrinologist or obesity medicine specialist can help integrate it into a long-term plan, and a genetic counselor can help your family understand what it means.

When Results Can Be Misleading

Genetic tests have their own set of confounders. The most important ones for MC3R:

• Variant panel coverage: the test only finds the specific changes it is designed to detect. A negative result rules out those changes, not every possible rare variant in MC3R.
• Ancestry and allele frequencies: some MC3R variants are more common in certain populations. The clinical meaning of a result can depend on your ancestry. Risk allele direction can also differ across populations, as seen with the rs6127698 tuberculosis findings.
• Variants of uncertain significance: an unexpected change may be reported with unknown clinical meaning. This is not the same as a known risk variant.
• Clinical-grade versus consumer testing: results from a consumer test like 23andMe should be confirmed with a clinical-grade assay before being used to drive medical decisions.

Carrying a Variant Does Not Mean Disease Is Inevitable

Even people with rare loss-of-function MC3R variants do not all become obese, develop diabetes, or grow up late. In the largest study to date, most homozygous loss-of-function carriers did not have a BMI in the obese range. Genetic variants raise the odds in some contexts; environment, diet, sleep, and activity still shape the outcome. The reason to know is that it lets you act earlier and more deliberately than someone learning their family pattern only after a diagnosis.